Filters
An association exists between magnetic resonance imaging (MRI) findings of localized prostate cancer and clinically relevant long-term oncologic outcomes, a study has found.
Treatment with 100-mg sildenafil appears to be the best strategy to improve erectile function recovery rates after radical prostatectomy, suggests a study. However, the on-demand dose of phosphodiesterase-5 (PDE5) inhibitors does not appear to be any better than placebo and must therefore not be considered as a penile rehabilitation strategy.
Prostate cancer seems to have no long-term adverse effects on survivors’ sexual, genitourinary, and general quality of life, a recent study has found.
Consumption of a newly developed whole tomato‑based food supplement* (WTFS) led to improvements in lower urinary tract symptoms** (LUTS) and quality of life (QoL) in men with benign prostatic hyperplasia (BPH), a phase II Italian study has shown.
Around-the-clock administration of intravenous acetaminophen lowers postoperative pain and the need for emergency analgesia after robot-assisted radical prostatectomy, a recent study has shown.
In children, dehiscence, severe recurrent ventral curvature, and urethral strictures all aggravate the risk of reoperation after primary hypospadias repair, a recent study.
In the treatment of vasculogenic erectile dysfunction (ED), low-intensity extracorporeal shockwave therapy (Li-ESWT) is safe and effective for some patients, particularly those with mild-to-moderate ED, a study suggests.
Adding apalutamide (APA) to abiraterone acetate and prednisone (AAP) significantly extends radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with AAP only, according to the final analysis of the ACIS* trial presented at ASCO GU 2021.
In an updated analysis of the phase III POUT* trial presented at ASCO GU 2021, peri-operative chemotherapy continued to improve disease-free survival (DFS) compared with surveillance in patients with upper tract urothelial cancer (UTUC).
Despite high rates of reoperation, most children on sacral neuromodulation (SNM) devices either continue to use these tools or experience symptom improvements enough to permit device removal in the moderate term, according to a new study.
